VYTRUS BIOTECH EO -01 (V5P) — Capital Reinvestment Ratio
Latest as of December 2025:
0.69x
VYTRUS BIOTECH EO -01 (V5P) has a Capital Reinvestment Ratio of 0.69x as of December 2025, meaning it reinvests 1% of its operating cash flow (€3.90 Million) in capital expenditures (€2.68 Million). See free cash flow generation of VYTRUS BIOTECH EO -01 to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.69x
Capex / Operating Cash Flow
Operating Cash Flow
€3.90 Million
EUR
Capital Expenditures
€2.68 Million
EUR
Data as of
Dec 2025
Most recent filing
VYTRUS BIOTECH EO -01 Capital Reinvestment Ratio (2021–2025)
This chart tracks VYTRUS BIOTECH EO -01's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for VYTRUS BIOTECH EO -01 (2021–2025)
Year-by-year Capital Reinvestment Ratio for VYTRUS BIOTECH EO -01 from 2021 to 2025. For live market cap and broader valuation context, see VYTRUS BIOTECH EO -01 stock valuation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.69x | €3.90 Million | €2.68 Million | ▲ +5.2% |
| 2024 | 0.65x | €1.84 Million | €1.20 Million | ▼ -49.4% |
| 2023 | 1.29x | €904.39K | €1.17 Million | ▲ +2.2% |
| 2022 | 1.26x | €1.03 Million | €1.29 Million | ▲ +107.9% |
| 2021 | 0.61x | €447.92K | €271.82K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow